Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Abbott seeks to market Xience V stent in Japan

Abbott Vascular : 02 June, 2008  (New Product)
Abbott has submitted an application for a Marketing Authorization License to Japan's Ministry of Health, Labour and Welfare (MHLW)/ Pharmaceuticals and Medical Devices Agency (PMDA) to gain approval for its Xience V Everolimus Eluting Coronary Stent System to treat coronary artery disease.
The application for Xience V consisted of safety and efficacy data from the SPIRIT III clinical trial, including data from a Japanese patient population. As previously reported, results from the SPIRIT III US pivotal clinical trial demonstrated the superiority of Xience V over Boston Scientific's TAXUS paclitaxel-eluting coronary Stent system in the primary endpoint of in-segment late loss at eight months.

'Results of the SPIRIT III Japan Registry were very similar with those of the US randomized clinical trial, which was the first head-to-head clinical trial to demonstrate the superiority of one drug eluting Stent over another drug eluting stent,' said Daniel Estay, divisional vice president, Abbott Vascular Asia Pacific and Japan. 'Xience V represents an advancement in drug eluting Stent science and reinforces Abbott's deep commitment to providing physicians and patients in Japan with leading technologies and products in cardiac and vascular care.'

The Xience V Stent utilises everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following Stent implantation, and is built upon Abbott's Multi-Link Vision Coronary Stent System, the world's market-leading bare metal stent. The Vision platform has a flexible design and facilitates ease of delivery, making it easier for physicians to maneuver the Stent and treat the diseased portion of the artery.

Abbott's submission for Xience V included data from SPIRIT III, a large-scale, randomised clinical trial of 1,002 patients conducted in the USA. The submission also included data from two non-randomised registry arms: the SPIRIT III Japan Registry of 88 patients and the SPIRIT III 4.0mm Registry of 69 patients conducted in the USA. Key results include:

Statistical superiority for Xience V compared to Taxus in the primary endpoint of in-segment late loss at eight months in the randomised clinical trial, where Xience V demonstrated a statistically significant 50 percent reduction in late loss compared to Taxus (mean, 0.14mm for Xience V vs 0.28mm for Taxus). In-segment late loss is a measure of vessel re-narrowing.

Statistical non-inferiority for Xience V compared to Taxus in the co-primary endpoint of target vessel failure (TVF) at nine months in the randomised clinical trial, where Xience V demonstrated an observed 20 percent reduction in TVF compared to Taxus (7.2 percent for Xience V vs. 9.0 percent for Taxus). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

An observed 43 percent reduction in major adverse cardiac events (MACE) at nine months (4.6 percent for Xience V vs. 8.1 percent for Taxus) with Xience V compared to Taxus in the randomised clinical trial. MACE is an important clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (TLR driven by lack of blood supply).

Positive results confirming the efficacy and safety of Xience V from the SPIRIT III Japan Registry. The Japan Registry met its primary endpoint of in-segment late loss at eight months. A full analysis of the SPIRIT III Japan Registry will be presented later this year.

'The strong, positive data indicate that Xience V is a true next-generation drug eluting Stent that combines advanced technology with outstanding clinical benefits in the treatment of coronary artery disease,' said Shigeru Saito, MD, FACC, FSCAI, FJCC, director, Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, and principal investigator for the SPIRIT III Japan Registry.



Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo